• LOGIN
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publication
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Rescue of Isolated GH Deficiency Type II (IGHD II) via Pharmacologic Modulation of GH-1 Splicing.
 

Rescue of Isolated GH Deficiency Type II (IGHD II) via Pharmacologic Modulation of GH-1 Splicing.

Options
  • Details
BORIS DOI
10.48350/95632
Date of Publication
October 2016
Publication Type
Article
Division/Institute

Universitätsklinik fü...

Departement Klinische...

Departement Klinische...

Author
Miletta, Maria Consolata
Departement Klinische Forschung, Forschungsgruppe Endokrinologie / Diabetologie / Metabolik (Pädiatrie)
Universitätsklinik für Kinderheilkunde
Petkovic, Vibor
Universitätsklinik für Kinderheilkunde
Departement Klinische Forschung, Forschungsgruppe Endokrinologie / Diabetologie / Metabolik (Pädiatrie)
Eblé, Andrée
Departement Klinische Forschung, Forschungsgruppe Endokrinologie / Diabetologie / Metabolik (Pädiatrie)
Flück Pandey, Christa Emmaorcid-logo
Universitätsklinik für Kinderheilkunde
Departement Klinische Forschung, Forschungsgruppe Endokrinologie / Diabetologie / Metabolik (Pädiatrie)
Mullis, Primus-Eugen
Departement Klinische Forschung, Endokrinologie / Diabetologie (Erwachsene)
Departement Klinische Forschung, Forschungsgruppe Endokrinologie / Diabetologie / Metabolik (Pädiatrie)
Universitätsklinik für Kinderheilkunde
Subject(s)

600 - Technology::610...

Series
Endocrinology
ISSN or ISBN (if monograph)
1945-7170
Publisher
Oxford University Press
Language
English
Publisher DOI
10.1210/en.2015-2038
PubMed ID
27253996
Description
Isolated GH deficiency (IGHD) type II, the autosomal dominant form of GHD, is mainly caused by mutations that affect splicing of GH-1. When misspliced RNA is translated, it produces a toxic 17.5-kDa GH isoform that reduces the accumulation and secretion of wild-type-human GH (wt-hGH). Usually, isolated GHD type II patients are treated with daily injections of recombinant human GH in order to maintain normal growth. However, this type of replacement therapy does not prevent toxic effects of the 17.5-kDa GH isoform on the pituitary gland, which can eventually lead to other hormonal deficiencies. Here, we tested the possibility to restore the constitutive splicing pattern of GH-1 by using butyrate, a drug that mainly acts as histone deacetylase inhibitor. To this aim, wt-hGH and/or different hGH-splice site mutants (GH-IVS3+2, GH-IVS3+6, and GH-ISE+28) were transfected in rat pituitary cells expressing human GHRH receptor (GHRHR) (GC-GHRHR). Upon butyrate treatment, GC-GHRHR cells coexpressing wt-hGH and each of the mutants displayed increased GH transcript level, intracellular GH content, and GH secretion when compared with the corresponding untreated condition. The effect of butyrate was most likely mediated by the alternative splicing factor/splicing factor 2. Overexpression of alternative ASF/SF2 in the same experimental setting, indeed, promoted the amount of full-length transcripts thus increasing synthesis and secretion of the 22-kDa GH isoform. In conclusion, our results support the hypothesis that modulation of GH-1 splicing pattern to increase the 22-kDa GH isoform levels can be clinically beneficial and hence a crucial challenge in GHD research.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/149913
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
endo3972.pdftextAdobe PDF1.01 MBpublisherpublished restricted
BORIS Portal
Bern Open Repository and Information System
Build: 360c85 [14.04. 8:05]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo